These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17649799)

  • 1. Decision guarantee in tumour marker analysis: a cut-off independent assessment.
    Bitterlich N; Schneider J
    Anticancer Res; 2007; 27(4A):1933-9. PubMed ID: 17649799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cut-off-independent tumour marker evaluation using ROC approximation.
    Bitterlich N; Schneider J
    Anticancer Res; 2007; 27(6C):4305-10. PubMed ID: 18214036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A fuzzy-classifier using a marker panel for the detection of lung cancers in asbestosis patients.
    Schneider J; Bitterlich N; Kotschy-Lang N; Raab W; Woitowitz HJ
    Anticancer Res; 2007; 27(4A):1869-77. PubMed ID: 17649786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Centre-independent detection of non-small cell lung cancer (NSCLC) by means of classification with receiver operating characteristic (ROC)-based data transformation.
    Bitterlich N; Muley T; Schneider J
    Anticancer Res; 2010 May; 30(5):1661-5. PubMed ID: 20592358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYFRA 21-1 in non-small cell lung cancer--standardisation and application during diagnosis.
    Pavićević R; Bubanović G; Franjević A; Stancić-Rokotov D; Samarzija M
    Coll Antropol; 2008 Jun; 32(2):485-98. PubMed ID: 18756899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fuzzy logic-based tumor marker profiles improved sensitivity of the detection of progression in small-cell lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Philipp M; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Clin Exp Med; 2003 Feb; 2(4):185-91. PubMed ID: 12624710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of lung cancer in silicosis patients using a tumor-marker panel.
    Schneider J
    Cancer Biomark; 2010; 6(3-4):137-48. PubMed ID: 20660960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fuzzy logic-based tumor-marker profiles improved sensitivity in the diagnosis of lung cancer.
    Schneider J; Bitterlich N; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Int J Clin Oncol; 2002 Jun; 7(3):145-51. PubMed ID: 12109515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma.
    Zhong LP; Zhu HG; Zhang CP; Chen WT; Zhang ZY
    Int J Oral Maxillofac Surg; 2007 Mar; 36(3):230-4. PubMed ID: 16965897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cut-off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN).
    Niemann AM; Goeroegh T; Gottschlich S; Lippert BM; Werner JA
    Anticancer Res; 1997; 17(4B):2859-60. PubMed ID: 9329547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas.
    Karnak D; Ulubay G; Kayacan O; Beder S; Ibis E; Oflaz G
    Lung; 2001; 179(1):57-65. PubMed ID: 11479694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of CYFRA 21-1, a new tumor marker, in nasopharyngeal carcinoma.
    Lin WY; Yen TC; Cheng KY; Wang SJ
    Neoplasma; 1998; 45(1):21-4. PubMed ID: 9604997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved sensitivity of fuzzy logic based tumor marker profiles for diagnosis of pancreatic carcinoma versus benign pancreatic disease.
    Halm U; Rohde N; Klapdor R; Reith HB; Thiede A; Etzrodt G; Mössner J; Keller T
    Anticancer Res; 2000; 20(6D):4957-60. PubMed ID: 11326646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer: comparison with serum levels of sialic acid, TPS and Cyfra 21-1.
    de Castro J; Rodríguez MC; Martínez-Zorzano VS; Hernández-Hernández A; Llanillo M; Sánchez-Yagüe J
    Cancer Invest; 2008 May; 26(4):407-18. PubMed ID: 18443962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
    Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
    Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
    Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK.
    Schneider J; Bitterlich N; Schulze G
    Anticancer Res; 2005; 25(3A):1507-15. PubMed ID: 16033052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.